Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2012

Open Access 01-12-2012 | Review

Review of patient-reported outcome measures in chronic hepatitis C

Authors: Leah Kleinman, Sally Mannix, Yong Yuan, Shannon Kummer, Gilbert L’Italien, Dennis Revicki

Published in: Health and Quality of Life Outcomes | Issue 1/2012

Login to get access

Abstract

Background

Chronic hepatitis C (CHC) and its treatment are associated with a variety of patient-reported symptoms and impacts. Some CHC symptoms and impacts may be difficult to evaluate through objective clinical testing, and more easily measured through patient self-report. This literature review identified concepts raised by CHC patients related to symptoms, impacts, and treatment effects, and evaluated integration of these concepts within patient-reported outcome (PRO) measures. The goal of this work was to provide recommendations for incorporation of PRO measurement of concepts that are relevant to the CHC experience into CHC clinical trial design.

Methods

A three-tiered literature search was conducted. This included searches on concepts of importance, PRO measures used in clinical trials, and existing PRO measures. The PRO Concept Search focused on reviewing issues raised by CHC patients about CHC symptoms, disease impact, and treatment effects. The CHC Trials with PRO Endpoints Search reviewed clinical trials with PRO endpoints to assess differences between treatments over time. The PRO Measure Search reviewed existing PRO measures associated with the concepts of interest.

Results

This multi-tiered approach identified five key concepts of interest: depression/anxiety, fatigue, flu-like symptoms, cognitive function, insomnia. Comparing these five concepts of interest to the PRO measures in published CHC clinical trials showed that, while treatment of CHC may decrease health-related quality of life in a number of mental and physical domains, the PRO measures that were utilized in published clinical trials inadequately covered the concepts of interest. Further review of 18 existing PRO measures of the concepts of interest showed only four of the 18 were validated in CHC populations.

Conclusions

This review identified several gaps in the literature regarding assessment of symptoms and outcomes reported as important by CHC patients. Further research is needed to ensure that CHC clinical trials evaluate concepts that are important to patients and include measures that have evidence supporting content validity, reliability, construct validity, and responsiveness.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J: Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002, 35(3):704–708. 10.1053/jhep.2002.31311CrossRefPubMed
4.
Dieperink E, Willenbring M, Ho SB: Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000, 157(6):867–876. 10.1176/appi.ajp.157.6.867CrossRefPubMed
5.
Conrad S, Garrett LE, Cooksley WG, Dunne MP, MacDonald GA: Living with chronic hepatitis C means 'you just haven't got a normal life any more'. Chronic Illn 2006, 2(2):121–131.PubMed
6.
Groessl EJ, Weingart KR, Kaplan RM, Clark JA, Gifford AL, Ho SB: Living with hepatitis C: qualitative interviews with hepatitis C-infected veterans. J Gen Intern Med 2008, 23(12):1959–1965. 10.1007/s11606-008-0790-yPubMedCentralCrossRefPubMed
7.
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347(13):975–982. 10.1056/NEJMoa020047CrossRefPubMed
8.
Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140(5):346–355.CrossRefPubMed
9.
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358(9286):958–965. 10.1016/S0140-6736(01)06102-5CrossRefPubMed
10.
Fraenkel L, McGraw S, Wongcharatrawee S, Garcia-Tsao G: Patients' experiences related to anti-viral treatment for hepatitis C. Patient Educ Couns 2006, 62(1):148–155. 10.1016/j.pec.2005.06.019CrossRefPubMed
11.
Scientific Advisory Committee of the Medical Outcomes Trust: Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002, 11(3):193–205. 10.1023/A:1015291021312CrossRef
12.
Turner RR, Quittner AL, Parasuraman BM, Kallich JD, Cleeland CS: Patient-reported outcomes: instrument development and selection issues. Value Health 2007, 10(Suppl 2):S86-S93.CrossRefPubMed
13.
FDA: Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist 2009, 74(235):65132–65133.
14.
Blasiole JA, Shinkunas L, Labrecque DR, Arnold RM, Zickmund SL: Mental and physical symptoms associated with lower social support for patients with hepatitis C. World J Gastroenterol 2006, 12(29):4665–4672.PubMedCentralPubMed
15.
Dunne EA, Quayle E: The impact of latrogenically acquired Hepatitis C infection on the well-being and relationships of a group of Irish women. J Health Psychol 2001, 6(6):679–692. 10.1177/135910530100600606CrossRefPubMed
16.
Glacken M, Coates V, Kernohan G, Hegarty J: The experience of fatigue for people living with hepatitis C. J Clin Nurs 2003, 12(2):244–252. 10.1046/j.1365-2702.2003.00709.xCrossRefPubMed
17.
Glacken M, Kernohan G, Coates V: Diagnosed with Hepatitis C: a descriptive exploratory study. Int J Nurs Stud 2001, 38(1):107–116. 10.1016/S0020-7489(00)00046-8CrossRefPubMed
18.
Hopwood M, Treloar C: The experience of interferon-based treatments for hepatitis C infection. Qual Health Res 2005, 15(5):635–646. 10.1177/1049732304273932CrossRefPubMed
19.
Hopwood M, Treloar C: Resilient coping: applying adaptive responses to prior adversity during treatment for hepatitis C infection. J Health Psychol 2008, 13(1):17–27. 10.1177/1359105307084308CrossRefPubMed
20.
Lang CA, Conrad S, Garrett L, Battistutta D, Cooksley WGE, Dunne MP, Macdonald GA: Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection. Journal of Pain and Symptom Management 2006, 31(4):335–344. 10.1016/j.jpainsymman.2005.08.016CrossRefPubMed
21.
Sheppard K, Hubbert A: The patient experience of treatment for hepatitis C. Gastroenterology nursing: the official journal of the Society of Gastroenterology Nurses and Associates 2006, 29(4):309–315. 10.1097/00001610-200607000-00008CrossRef
22.
Sutton R, Treloar C: Chronic illness experiences, clinical markers and living with hepatitis C. J Health Psychol 2007, 12(2):330–340. 10.1177/1359105307074278CrossRefPubMed
23.
Taylor-Young P, Hildebrandt E: The multidimensional burden of hepatitis C and its treatment: a case study. Gastroenterol Nurs 2009, 32(3):180–187. 10.1097/SGA.0b013e3181a80655CrossRefPubMed
24.
Teixeira PA, Schackman BR: Can urban methadone patients complete health utility assessments? Patient Education and Counseling 2008, 71(2):302–307. 10.1016/j.pec.2008.01.010PubMedCentralCrossRefPubMed
25.
Treloar C, Holt M: Drug treatment clients' readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings. Aust Health Rev 2008, 32(3):570–576. 10.1071/AH080570CrossRefPubMed
26.
Zickmund SL, Bryce CL, Blasiole JA, Shinkunas L, LaBrecque DR, Arnold RM: Majority of patients with hepatitis C express physical, mental, and social difficulties with antiviral treatment. Eur J Gastroenterol Hepatol 2006, 18(4):381–388. 10.1097/00042737-200604000-00011CrossRefPubMed
27.
Fraser S, Treloar C: 'Spoiled identity' in hepatitis C infection: the binary logic of despair. Crit Pub Health 2006, 16(2):99–110. 10.1080/09581590600828683CrossRef
28.
Grow JM, Christopher SA: Breaking the silence surrounding hepatitis C by promoting self-efficacy: hepatitis C public service announcements. Qual Health Res 2008, 18(10):1401–1412. 10.1177/1049732308322603CrossRefPubMed
29.
Janke EA, McGraw S, Garcia-Tsao G, Fraenkel L: Psychosocial issues in hepatitis C: a qualitative analysis. Psychosomatics 2008, 49(6):494–501. 10.1176/appi.psy.49.6.494PubMedCentralCrossRefPubMed
30.
Schafer A, Scheurlen M, Felten M, Kraus MR: Physician-patient relationship and disclosure behaviour in chronic hepatitis C in a group of German outpatients. Eur J Gastroenterol Hepatol 2005, 17(12):1387–1394. 10.1097/00042737-200512000-00019CrossRefPubMed
31.
Grundy G, Beeching N: Understanding social stigma in women with hepatitis C. Nurs Stand (R Coll Nurs G B: 1987) 2004, 19(4):35–39.CrossRef
32.
Rowan PJ, Dunn NJ, El-Serag HB, Kunik ME: Views of hepatitis C virus patients delayed from treatment for psychiatric reasons. J Viral Hepat 2007, 14(12):883–889.PubMed
33.
Arora S, O'Brien C, Zeuzem S, Shiffman ML, Diago M, Tran A, Pockros PJ, Reindollar RW, Gane E, Patel K, Wintfeld N, Green J: Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon (alpha)-2a (40 kDa) plus ribavirin: impact on health-related quality of life. J Gastroenterol Hepatol 2006, 21(2):406–412. 10.1111/j.1440-1746.2005.04059.xCrossRefPubMed
34.
Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, Pastore G, Trejo-Estrada R, Horta EVA, Wintfeld N, Green J: The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol 2004, 40(4):675–681. 10.1016/j.jhep.2003.12.014CrossRefPubMed
35.
Nayman Alpat S, Usluer G, Yavuz H, Doyuk Kartal E, Erben N, Bal C, Ozgunes I: Effect of pegylated interferon treatments for chronic active hepatitis C on quality of life. J Chemother 2008, 20(1):101–105.CrossRefPubMed
36.
Rasenack J, Zeuzem S, Feinman SV, Heathcote EJ, Manns M, Yoshida EM, Swain MG, Gane E, Diago M, Revicki DA, Lin A, Wintfeld N, Green J: Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacol Econ 2003, 21(5):341–349. 10.2165/00019053-200321050-00005CrossRef
37.
Perrillo R, Rothstein KD, Rubin R, Alam I, Imperial J, Harb G, Hu S, Klaskala W: Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. J Viral Hepat 2004, 11(2):157–165. 10.1046/j.1365-2893.2003.00482.xCrossRefPubMed
38.
Neri S, Pulvirenti D, Bertino G: Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: Comparison between interferon-(alpha)-2a and interferon-(alpha)-2b. Clin Drug Investig 2006, 26(11):655–662. 10.2165/00044011-200626110-00005CrossRefPubMed
39.
Bayliss MS, Gandek B, Bungay KM, Sugano D, Hsu MA, Ware JE Jr: A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998, 7(1):39–55.CrossRefPubMed
40.
Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL: Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999, 30(2):550–555. 10.1002/hep.510300203CrossRefPubMed
41.
Kleinman L, Zodet MW, Hakim Z, Aledort J, Barker C, Chan K, Krupp L, Revicki D: Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res 2000, 9(5):499–508. 10.1023/A:1008960710415CrossRefPubMed
42.
Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D: Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999, 45(2):295–300. 10.1136/gut.45.2.295PubMedCentralCrossRefPubMed
43.
Leidy NK, Palmer C, Murray M, Robb J, Revicki DA: Health-related quality of life assessment in euthymic and depressed patients with bipolar disorder. Psychometric performance of four self-report measures. J Affect Disord 1998, 48(2–3):207–214.CrossRefPubMed
44.
Stewart AL, Ware JE Jr, Sherbourne CD, Wells KB: Psychological distress/well-being and cognitive functioning measures. In Measuring Functioning and Well-being: The Medical Outcomes Study Approach. Edited by: Stewart AL, Ware JE, Durham NC. Duke University Press; 1992:102–142. 381–394
45.
Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, Ader D, Fries JF, Bruce B, Rose M: The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 2007, 45(5 Suppl 1):S3-S11.PubMedCentralCrossRefPubMed
46.
Christodoulou C, Junghaenel DU, DeWalt DA, Rothrock N, Stone AA: Cognitive interviewing in the evaluation of fatigue items: results from the patient-reported outcomes measurement information system (PROMIS). Qual Life Res 2008, 17(10):1239–1246. 10.1007/s11136-008-9402-xPubMedCentralCrossRefPubMed
47.
48.
Revicki DA, Kawata AK, Harnam N, Chen WH, Hays RD, Cella D: Predicting EuroQol (EQ-5D) scores from the patient-reported outcomes measurement information system (PROMIS) global items and domain item banks in a United States sample. Qual Life Res 2009, 18(6):783–791. 10.1007/s11136-009-9489-8PubMedCentralCrossRefPubMed
49.
Gralnek IM, Hays RD, Kilbourne A, Rosen HR, Keeffe EB, Artinian L, Kim S, Lazarovici D, Jensen DM, Busuttil RW, Martin P: Development and evaluation of the Liver Disease Quality of Life instrument in persons with advanced, chronic liver disease–the LDQOL 1.0. Am J Gastroenterol 2000, 95(12):3552–3565.PubMed
50.
Gutteling JJ, de Man RA, van der Plas SM, Schalm SW, Busschbach JJ, Darlington AS: Determinants of quality of life in chronic liver patients. Aliment Pharmacol Ther 2006, 23(11):1629–1635. 10.1111/j.1365-2036.2006.02934.xCrossRefPubMed
51.
van der Plas SM, Hansen BE, de Boer JB, Stijnen T, Passchier J, de Man RA, Schalm SW: The Liver Disease Symptom Index 2.0; validation of a disease-specific questionnaire. Qual Life Res 2004, 13(8):1469–1481.CrossRefPubMed
Metadata
Title
Review of patient-reported outcome measures in chronic hepatitis C
Authors
Leah Kleinman
Sally Mannix
Yong Yuan
Shannon Kummer
Gilbert L’Italien
Dennis Revicki
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2012
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-10-92

Other articles of this Issue 1/2012

Health and Quality of Life Outcomes 1/2012 Go to the issue

Research

Factors associated with health-related quality of life among Chinese caregivers of the older adults living in the community: a cross-sectional study

Research

An exploratory study of the perceived impact of health problems of landmine/UXO victims versus another disability group

Research

Posttraumatic growth, depressive symptoms, posttraumatic stress symptoms, post-migration stressors and quality of life in multi-traumatized psychiatric outpatients with a refugee background in Norway

Research

Improvement of health-related quality of life in depression after transcranial magnetic stimulation in a naturalistic trial is associated with decreased perfusion in precuneus

Research

Distance saturation product predicts health–related quality of life among sarcoidosis patients

Research

Quality of life themes in Canadian adults and street youth who are homeless or hard-to-house: A multi-site focus group study